Standing desks could decrease heart disease

“This is why we feel invigorated after exercises and lethargic after sitting all day. By not moving enough the brain

Expectant mother’s BP impacts child’s risk of obesity

Childhood obesity has become an international public health problem. An estimated 42 million children ages 5 and younger met the

SA interventional cardiologist demonstrates repair procedure

Professor Hellig, a renowned interventional cardiologist and associate professor at the University of Cape Town’s Medical School, spoke participants through

High blood pressure remains undiagnosed

It is estimated that 40% of South Africans suffer from hypertension but that only approximately half of them are aware

Angina is common, but frequently undertreated

Ischaemic heart disease (IHD) is a major contributor to CVD in this country. It is one of the 10 leading

State-of-the-art cardiac pacing procedure performed

The successful procedure was performed on a 75-year-old patient, who initially was treated for type 2 diabetes mellitus and chronic renal impairment by specialist

Erectile dysfunction an early marker of CVD

ED is defined as the ‘inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance’. It is commonly

Would you recognise the symptoms of a stroke?

The golden rule when a person has a stroke is for them to get medical attention as soon as possible,”

Shockwave IVL technology makes its SA debut

Shockwave IVL is a novel system that delivers localised pulsatile sonic pressure waves, modifying calcified lesions in a safe and

Rooibos’ ability to curb heart disease undeniable

New research indicates that the humble rooibos bush might be at the frontline of preventative therapies for cardiovascular disease and the mortality risks associated with it.

Fighting the world’s biggest killer

Around 50% people with hypertension are unaware of their condition. Of those who are aware, half do not take any action to control their blood pressure.

Rivaroxaban approved as CV event prevention treatment in CAD and PAD

Janssen has announced that the FDA has approved its factor Xa inhibitor rivaroxaban for reduction of risk for major adverse CV events in patients with chronic CAD or peripheral artery disease.